Plasma cells as an innovative target in autoimmune disease with renal manifestations

Nature Reviews Nephrology

Volumn 12, Issue 4, 2016, Pages 232-240

  Hiepe, Falk ^a   Radbruch, Andreas ^a  

^a DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PROTEASOME INHIBITOR; THYMOCYTE ANTIBODY; AUTOANTIBODY; BORONIC ACID DERIVATIVE; BORTEZOMIB; CARFILZOMIB; CTCE-9908; DELANZOMIB; OLIGOPEPTIDE; PEPTIDE; THREONINE;

ADVERSE DRUG REACTION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL HOMING; CELL SURFACE; CELL SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY DISEASE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TARGET CELL; ANALOGS AND DERIVATIVES; AUTOIMMUNE DISEASES; B LYMPHOCYTE; GLOMERULONEPHRITIS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; KIDNEY DISEASES; LUPUS NEPHRITIS;

AUTOANTIBODIES; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; BORONIC ACIDS; BORTEZOMIB; GLOMERULONEPHRITIS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; LUPUS NEPHRITIS; OLIGOPEPTIDES; PEPTIDES; PLASMA CELLS; PROTEASOME INHIBITORS; THREONINE;

EID: 84959189546     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2016.20     Document Type: Review

References (105)

1. Fagraeus A. Plasma cellular reaction and its relation to the formation of antibodies in vitro. Nature 159, 499 (1947
2. Szakal A. K., Kosco M. H., & Tew J. G. Microanatomy of lymphoid tissue during humoral immune responses: structure function relationships. Annu. Rev. Immunol. 7, 91-109 (1989
3. Zinkernagel R. M., et al. On immunological memory. Annu. Rev. Immunol. 14, 333-367 (1996
4. Miller J. J., 3rd, & Cole L. J. Resistance of long-lived lymphocytes and plasma cells in rat lymph nodes to treatment with prednisone, cyclophosphamide, 6 mercaptopurine, and actinomycin D. J. Exp. Med. 126, 109-125 (1967
5. Okudaira H., & Ishizaka K. Reaginic antibody formation in the mouse. XI. Participation of long-lived antibody-forming cells in persistent antibody formation. Cell. Immunol. 58, 188-201 (1981
6. Ho F., Lortan J. E., MacLennan I. C., & Khan M. Distinct short-lived and long-lived antibody-producing cell populations. Eur. J. Immunol. 16, 1297-1301 (1986
7. Manz R. A., Thiel A., & Radbruch A. Lifetime of plasma cells in the bone marrow. Nature 388, 133-134 (1997
8. Slifka M. K., Antia R., Whitmire J. K., & Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 8, 363-372 (1998
9. Hoyer B. F., et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J. Exp. Med. 199, 1577-1584 (2004
10. Manz R., Hauser A., Hiepe F., & Radbruch A. Maintenance of serum antibody levels. Annu. Rev. Immunol. 23, 367-386 (2005
11. Baumgarth N. Innate-like B cells and their rules of engagement. Adv. Exp. Med. Biol. 785, 57-66 (2013
12. Garraud O., et al. Revisiting the B cell compartment in mouse and humans: more than one B cell subset exists in the marginal zone and beyond. BMC Immunol. 13, 63 (2012
13. Nutt S. L., Hodgkin P. D., Tarlinton D. M., & Corcoran L. M. The generation of antibody-secreting plasma cells. Nat. Rev. Immunol. 15, 160-171 (2015
14. Radbruch A., et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6, 741-750 (2006
15. Weisel F. J., Zuccarino-Catania G. V., Chikina M., & Shlomchik M. J. A. Temporal switch in the germinal center determines differential output of memory B and plasma cells. Immunity 44, 116-130 (2016
16. Tarlinton D., Radbruch A., Hiepe F., & Dörner T. Plasma cell differentiation and survival. Curr. Opin. Immunol. 20, 162-169 (2008
17. Porstner M., et al. miR 148a promotes plasma cell differentiation and targets the germinal center transcription factors Mitf and Bach2. Eur. J. Immunol. 45, 1206-1215 (2015
18. Mei H. E., et al. A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. Blood 125, 1739-1748 (2015
19. Halliley J. L., et al. Long-lived plasma cells are contained within the CD19-CD38hiCD138+ subset in human bone marrow. Immunity 43, 132-145 (2015
20. Shen P., et al. IL 35 producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature 507, 366-370 (2014
21. Dang V. D., Hilgenberg E., Ries S., Shen P., & Fillatreau S. From the regulatory functions of B cells to the identification of cytokine-producing plasma cell subsets. Curr. Opin. Immunol. 28, 77-83 (2014
22. Tokoyoda K., Hauser A. E., Nakayama T., & Radbruch A. Organization of immunological memory by bone marrow stroma. Nat. Rev. Immunol. 10, 193-200 (2010
23. Tokoyoda K., Egawa T., Sugiyama T., Choi B. I., & Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 20, 707-718 (2004
24. Pengo N., et al. Plasma cells require autophagy for sustainable immunoglobulin production. Nat. Immunol. 14, 298-305 (2013
25. Cassese G., et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J. Immunol. 171, 1684-1690 (2003
26. Minges Wols H. A., Underhill G. H., Kansas G. S., & Witte P. L. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J. Immunol. 169, 4213-4221 (2002
27. Hargreaves D. C., et al. A coordinated change in chemokine responsiveness guides plasma cell movements. J. Exp. Med. 194, 45-56 (2001
28. Winter O., Dame C., Jundt F., & Hiepe F. Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. J. Immunol. 189, 5105-5111 (2012
29. Rozanski C. H., et al. Sustained antibody responses depend on CD28 function in bone marrow-resident plasma cells. J. Exp. Med. 208, 1435-1446 (2011
30. Chevrier S., et al. CD93 is required for maintenance of antibody secretion and persistence of plasma cells in the bone marrow niche. Proc. Natl Acad. Sci. USA 106, 3895-3900 (2009
31. Winter O., et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood 116, 1867-1875 (2010
32. Chu V. T., et al. Eosinophils are required for the maintenance of plasma cells in the bone marrow. Nat. Immunol. 12, 151-159 (2011
33. Peperzak V., et al. Mcl 1 is essential for the survival of plasma cells. Nat. Immunol. 14, 290-297 (2013
34. Balabanian K., et al. Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J. Immunol. 170, 3392-3400 (2003
35. Szyszko E. A., et al. Salivary glands of primary Sjogren?s syndrome patients express factors vital for plasma cell survival. Arthritis Res. Ther. 13, R2 (2011
36. Lacotte S., et al. Early sifferentiated CD138highMHCII+IgG+ plasma cells express CXCR3 and localize into inflamed kidneys of lupus mice. PLoS ONE 8, e58140 (2013
37. Belnoue E., et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 111, 2755-2764 (2008
38. Benson M. J., et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J. Immunol. 180, 3655-3659 (2008
39. Shah H. B., et al. BAFF-and APRIL-dependent maintenance of antibody titers after immunization with t dependent antigen and CD1d binding ligand. J. Immunol. 191, 1154-1163 (2013
40. Manz R. A., Löhning M., Cassese G., Thiel A., & Radbruch A. Survival of long-lived plasma cells is independent of antigen. Int. Immunol. 10, 1703-1711 (1998
41. Ahuja A., Anderson S. M., Khalil A., & Shlomchik M. J. Maintenance of the plasma cell pool is independent of memory B cells. Proc. Natl Acad. Sci. USA 105, 4802-4807 (2008
42. DiLillo D. J., et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J. Immunol. 180, 361-371 (2008
43. Couser W. G., & Johnson R. J. The etiology of glomerulonephritis: roles of infection and autoimmunity. Kidney Int. 86, 905-914 (2014
44. Kurts C., Panzer U., Anders H. J., & Rees A. J. The immune system and kidney disease: basic concepts and clinical implications. Nat. Rev. Immunol. 13, 738-753 (2013
45. Martin F., & Chan A. C. B cell immunobiology in disease: evolving concepts from the clinic. Annu. Rev. Immunol. 24, 467-496 (2006
46. Hiepe F., et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat. Rev. Rheumatol. 7, 170-178 (2011
47. Cheng Q., et al. Autoantibodies from long-lived memory plasma cells of NZB/W mice drive immune complex nephritis. Ann. Rheum. Dis. 72, 2011-2017 (2013
48. Manz R. A., Hauser A. E., Hiepe F., & Radbruch A. Maintenance of serum antibody levels. Annu. Rev. Immunol. 23, 367-386 (2005
49. Odendahl M., et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 165, 5970-5979 (2000
50. Jacobi A. M., et al. HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 69, 305-308 (2010
51. Hoyer B. F., et al. Role of plasma cell analysis as a biomarker for disease activity in patients with granulomatosis with polyangiitis. Ann. Rheum. Dis. 72, 924-924 (2013
52. Odendahl M., et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105, 1614-1621 (2005
53. Wrammert J., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667-671 (2008
54. Tipton C. M., et al. Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus. Nat. Immunol. 16, 755-765 (2015
55. Mumtaz I. M., et al. Bone marrow of NZB/W mice is the major site for plasma cells resistant to dexamethasone and cyclophosphamide: implications for the treatment of autoimmunity. J. Autoimmun 39, 180-188 (2012
56. Espeli M., et al. Local renal autoantibody production in lupus nephritis. J. Am. Soc. Nephrol. 22, 296-305 (2011
57. Cassese G., et al. Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur. J. Immunol. 31, 2726-2732 (2001
58. Starke C., et al. High frequency of autoantibody-secreting cells and long-lived plasma cells within inflamed kidneys of NZB/W F1 lupus mice. Eur. J. Immunol. 41, 2107-2112 (2011
59. Lacotte S., Dumortier H., Decossas M., Briand J. P., & Muller S. Identification of new pathogenic players in lupus: autoantibody-secreting cells are present in nephritic kidneys of (NZBxNZW)F1 mice. J. Immunol. 184, 3937-3945 (2010
60. Chu V. T., et al. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum. 60, 2083-2093 (2009
61. Zand M. S., et al. Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin. Blood 107, 2895-2903 (2006
62. Popow I., et al. A comprehensive and quantitative analysis of the major specificities in rabbit antithymocyte globulin preparations. Am. J. Transplant. 13, 3103-3113 (2013
63. Alexander T., et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 113, 214-223 (2009
64. Muraro P. A., et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J. Exp. Med. 201, 805-816 (2005
65. Delemarre E. M., et al. Autologous stem cell transplantation aids autoimmune patients by functional renewal and TCR diversification of regulatory T cells. Blood 127, 91-101 (2016
66. Meister S., et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 67, 1783-1792 (2007
67. Neubert K., et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat. Med. 14, 748-755 (2008
68. Alexander T., et al. The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann. Rheum. Dis. 74, 1474-1478 (2015
69. Ichikawa H. T., et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum. 64, 493-503 (2012
70. Blanco B., et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 107, 3575-3583 (2006
71. Maseda D., Meister S., Neubert K., Herrmann M., & Voll R. E. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development. Cell Death Differ. 15, 600-612 (2008
72. Bontscho J., et al. Myeloperoxidase-specific plasma cell depletion by bortezomib protects from anti-neutrophil cytoplasmic autoantibodies-induced glomerulonephritis. J. Am. Soc. Nephrol. 22, 336-348 (2011
73. Novikov P., Moiseev S., Bulanov N., & Shchegoleva E. Bortezomib in refractory ANCA-associated vasculitis: a new option? Ann. Rheum. Dis. 75, e9 (2015
74. Hartono C., Chung M., Kuo S. F., Seshan S. V., & Muthukumar T. Bortezomib therapy for nephrotic syndrome due to idiopathic membranous nephropathy. J. Nephrol. 27, 103-106 (2014
75. Ejaz N. S., et al. Review of bortezomib treatment of antibody-mediated rejection in renal transplantation. Antioxid. Redox Signal. 21, 2401-2418 (2014
76. Seavey M. M., Lu L. D., Stump K. L., Wallace N. H., & Ruggeri B. A. Novel, orally active, proteasome inhibitor, delanzomib (CEP 18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. Int. Immunopharmacol. 12, 257-270 (2012
77. van Vollenhoven R. F., Wax S., Li Y., & Tak P. P. Safety and efficacy of atacicept in combination with rituximab for reducing the signs and symptoms of rheumatoid arthritis: a Phase II, randomized, double-blind, placebo-controlled pilot trial. Arthritis Rheum. 67, 2828-2836 (2015
78. Isenberg D., et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to severe systemic lupus erythematosus (SLE): 52 week data (APRIL-SLE randomised trial). Ann. Rheum. Dis. 74, 2006-2015 (2015
79. Kappos L., et al. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, Phase 2 trial. Lancet Neurol. 13, 353-363 (2014
80. Sergott R. C., et al. ATON: results from a Phase II randomized trial of the B cell-targeting agent atacicept in patients with optic neuritis. J. Neurol. Sci. 351, 174-178 (2015
81. Genovese M. C., Kinnman N., de La Bourdonnaye G., Pena Rossi C., & Tak P. P. Atacicept in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor antagonist therapy: results of a Phase II, randomized, placebo-controlled, dose-finding trial. Arthritis Rheum. 63, 1793-1803 (2011
82. van Vollenhoven R. F., Kinnman N., Vincent E., Wax S., & Bathon J. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a Phase II, randomized, placebo-controlled trial. Arthritis Rheum. 63, 1782-1792 (2011
83. Khodadadi L., et al. Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB/W F1 mice. PLoS ONE 10, e0135081 (2015
84. Wang A., et al. CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus. J. Immunol. 182, 4448-4458 (2009
85. Meller S., et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum. 52, 1504-1516 (2005
86. De Klerck B., et al. Pro-inflammatory properties of stromal cell-derived factor 1 (CXCL12) in collagen-induced arthritis. Arthritis Res. Ther. 7, R1208-R1220 (2005
87. Buckley C. D., et al. Persistent induction of the chemokine receptor CXCR4 by TGF-β 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J. Immunol. 165, 3423-3429 (2000
88. Liu C. L., Lyle M. J., Shin S. C., & Miao C. H. Strategies to target long-lived plasma cells for treating hemophilia A inhibitors. Cell. Immunol. http://dx.doi.org/10.1016/j.cellimm.2016.01.005 (2016
89. Arce S., et al. CD38 low IgG-secreting cells are precursors of various CD38 high-expressing plasma cell populations. J. Leukocyte Biol. 75, 1022-1028 (2004
90. Lin P., Owens R., Tricot G., & Wilson C. S. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am. J. Clin. Pathol. 121, 482-488 (2004
91. Santonocito A. M., et al. Flow cytometric detection of aneuploid CD38++ plasmacells and CD19+ B lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients. Leuk. Res. 28, 469-477 (2004
92. Lokhorst H. M., et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N. Engl. J. Med. 373, 1207-1219 (2015
93. Wong S. W., & Comenzo R. L. CD38 monoclonal antibody therapies for multiple myeloma. Clin. Lymphoma Myeloma Leuk. 15, 635-645 (2015
94. Ginzler E. M., et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res. Ther. 14, R33 (2012
95. Ljungman P., et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant. 35, 737-746 (2005
96. Yoshida T., et al. Gene expression profiles of plasmablasts and plasma cells differ in SLE versus protective immunity. Ann. Rheum. Dis. 66 (Suppl. 2), 307 (2007
97. Lugar P. L., Love C., Grammer A. C., Dave S. S., & Lipsky P. E. Molecular characterization of circulating plasma cells in patients with active systemic lupus erythematosus. PLoS ONE 7, e44362 (2012
98. Köhler G., & Shulman M. J. Immunoglobulin M mutants. Eur. J. Immunol. 10, 467-476 (1980
99. Köhler G., Potash M. J., Lehrach H., & Shulman M. J. Deletions in immunoglobulin mu chains. EMBO J. 1, 555-563 (1982
100. Manz R., Assenmacher M., Pfluger E., Miltenyi S., & Radbruch A. Analysis and sorting of live cells according to secreted molecules, relocated to a cell-surface affinity matrix. Proc. Natl Acad. Sci. USA 92, 1921-1925 (1995
101. Taddeo A., et al. Selection and depletion of plasma cells hbased on the specificity of the secreted antibody. Eur. J. Immunol. 45, 317-319 (2015
102. Taddeo A., et al. Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors. Arthritis Res. Ther. 17, 39 (2015
103. Hoyer B., et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. Arthritis Res. Ther. 6, S3-S4 (2004
104. Cambridge G., et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48, 2146-2154 (2003
105. Stohl W., et al. Belimumab reduces autoantibodies, normalizes low complement, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 64, 2328-2337 (2012